Thomas Campbell
Concepts (610)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 109 | 2024 | 2453 | 6.840 |
Why?
| Sarcoma, Kaposi | 23 | 2024 | 68 | 5.340 |
Why?
| HIV-1 | 61 | 2023 | 768 | 4.910 |
Why?
| Anti-HIV Agents | 46 | 2023 | 663 | 4.320 |
Why?
| Herpesvirus 8, Human | 22 | 2024 | 61 | 3.510 |
Why?
| Antiretroviral Therapy, Highly Active | 30 | 2023 | 256 | 2.650 |
Why?
| AIDS-Related Opportunistic Infections | 12 | 2021 | 115 | 1.850 |
Why?
| Anti-Retroviral Agents | 20 | 2019 | 207 | 1.830 |
Why?
| Viral Load | 34 | 2023 | 405 | 1.500 |
Why?
| Acquired Immunodeficiency Syndrome | 7 | 2023 | 212 | 1.470 |
Why?
| HIV Seropositivity | 7 | 2021 | 109 | 1.400 |
Why?
| Zimbabwe | 17 | 2023 | 41 | 1.350 |
Why?
| International Cooperation | 4 | 2018 | 169 | 1.240 |
Why?
| CD4 Lymphocyte Count | 26 | 2023 | 256 | 1.100 |
Why?
| Education, Medical | 3 | 2018 | 214 | 1.060 |
Why?
| Aging | 8 | 2020 | 1611 | 1.000 |
Why?
| RNA, Viral | 19 | 2014 | 565 | 0.940 |
Why?
| Physical Fitness | 2 | 2015 | 180 | 0.870 |
Why?
| Male | 110 | 2023 | 55396 | 0.840 |
Why?
| Adult | 92 | 2023 | 30375 | 0.830 |
Why?
| DNA, Viral | 12 | 2013 | 349 | 0.830 |
Why?
| Tuberculosis | 7 | 2023 | 241 | 0.820 |
Why?
| Humans | 153 | 2024 | 114045 | 0.810 |
Why?
| Middle Aged | 69 | 2023 | 26605 | 0.800 |
Why?
| Drug Resistance, Viral | 8 | 2015 | 99 | 0.780 |
Why?
| Antibodies, Viral | 8 | 2023 | 520 | 0.780 |
Why?
| Viremia | 6 | 2011 | 122 | 0.770 |
Why?
| Herpesviridae Infections | 7 | 2021 | 138 | 0.760 |
Why?
| Female | 104 | 2023 | 59324 | 0.750 |
Why?
| CD4-Positive T-Lymphocytes | 12 | 2023 | 959 | 0.730 |
Why?
| Coinfection | 6 | 2019 | 120 | 0.720 |
Why?
| AIDS Dementia Complex | 7 | 2015 | 50 | 0.710 |
Why?
| Nursing Staff, Hospital | 1 | 2022 | 123 | 0.680 |
Why?
| Granulocyte Colony-Stimulating Factor | 4 | 2004 | 70 | 0.670 |
Why?
| Reverse Transcriptase Inhibitors | 6 | 2015 | 82 | 0.660 |
Why?
| Lamivudine | 6 | 2017 | 59 | 0.650 |
Why?
| Lipopolysaccharide Receptors | 2 | 2021 | 81 | 0.640 |
Why?
| Hematopoietic Stem Cell Mobilization | 3 | 2004 | 20 | 0.640 |
Why?
| Anemia | 3 | 2023 | 143 | 0.630 |
Why?
| Inflammation | 14 | 2023 | 2464 | 0.630 |
Why?
| Vitamin D Deficiency | 3 | 2017 | 158 | 0.620 |
Why?
| Vitamin D | 5 | 2018 | 340 | 0.600 |
Why?
| HIV | 8 | 2023 | 208 | 0.590 |
Why?
| Plasma | 4 | 2015 | 181 | 0.560 |
Why?
| Prospective Studies | 21 | 2022 | 6195 | 0.540 |
Why?
| Micronutrients | 4 | 2018 | 77 | 0.540 |
Why?
| Burnout, Professional | 1 | 2022 | 323 | 0.540 |
Why?
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 20 | 0.530 |
Why?
| Health Resources | 5 | 2019 | 120 | 0.520 |
Why?
| Internationality | 5 | 2019 | 143 | 0.510 |
Why?
| Motor Activity | 3 | 2015 | 635 | 0.510 |
Why?
| Quality of Life | 6 | 2019 | 2343 | 0.510 |
Why?
| Developing Countries | 10 | 2020 | 231 | 0.510 |
Why?
| RNA, Catalytic | 4 | 1997 | 181 | 0.490 |
Why?
| Awareness | 1 | 2015 | 93 | 0.480 |
Why?
| Antibiotics, Antineoplastic | 3 | 2023 | 110 | 0.470 |
Why?
| Benzoxazines | 6 | 2017 | 28 | 0.470 |
Why?
| Zidovudine | 7 | 2017 | 77 | 0.460 |
Why?
| C-Reactive Protein | 5 | 2015 | 362 | 0.450 |
Why?
| Biomarkers | 13 | 2023 | 3397 | 0.450 |
Why?
| HIV Integrase Inhibitors | 1 | 2015 | 62 | 0.450 |
Why?
| Bronchoalveolar Lavage Fluid | 6 | 2021 | 580 | 0.440 |
Why?
| Monocytes | 2 | 2023 | 503 | 0.430 |
Why?
| Gastrointestinal Microbiome | 4 | 2021 | 502 | 0.430 |
Why?
| Cytomegalovirus Infections | 1 | 2015 | 180 | 0.420 |
Why?
| Treatment Outcome | 21 | 2021 | 9049 | 0.420 |
Why?
| Immune Reconstitution Inflammatory Syndrome | 4 | 2020 | 18 | 0.410 |
Why?
| Malnutrition | 3 | 2018 | 62 | 0.390 |
Why?
| Aged | 23 | 2023 | 18969 | 0.390 |
Why?
| Sarcopenia | 1 | 2013 | 63 | 0.390 |
Why?
| Receptors, CCR5 | 5 | 2021 | 54 | 0.380 |
Why?
| Faculty, Medical | 4 | 2018 | 226 | 0.370 |
Why?
| Cross-Sectional Studies | 10 | 2022 | 4402 | 0.360 |
Why?
| Homosexuality, Male | 4 | 2021 | 169 | 0.350 |
Why?
| Accidental Falls | 1 | 2012 | 151 | 0.350 |
Why?
| Virus Replication | 6 | 2006 | 395 | 0.350 |
Why?
| South America | 7 | 2020 | 52 | 0.350 |
Why?
| Osteoporosis | 1 | 2013 | 224 | 0.350 |
Why?
| Antiviral Agents | 5 | 2017 | 642 | 0.350 |
Why?
| Africa | 6 | 2020 | 92 | 0.340 |
Why?
| Neutropenia | 1 | 2010 | 123 | 0.340 |
Why?
| Tenofovir | 6 | 2017 | 204 | 0.340 |
Why?
| Sexual Behavior | 4 | 2020 | 434 | 0.340 |
Why?
| Antineoplastic Agents, Phytogenic | 3 | 2020 | 181 | 0.330 |
Why?
| Drug Therapy, Combination | 10 | 2020 | 949 | 0.330 |
Why?
| Health Services Accessibility | 1 | 2015 | 756 | 0.330 |
Why?
| Advance Care Planning | 1 | 2012 | 195 | 0.320 |
Why?
| Drug Monitoring | 1 | 2010 | 184 | 0.320 |
Why?
| Viral Proteins | 2 | 2008 | 281 | 0.310 |
Why?
| Thrombocytopenia | 1 | 2010 | 177 | 0.310 |
Why?
| Emergency Medical Services | 1 | 2015 | 581 | 0.310 |
Why?
| Sexual and Gender Minorities | 3 | 2021 | 138 | 0.310 |
Why?
| Sex Characteristics | 3 | 2023 | 636 | 0.300 |
Why?
| Genetic Variation | 4 | 2008 | 868 | 0.300 |
Why?
| Microbiota | 4 | 2018 | 648 | 0.300 |
Why?
| Cohort Studies | 20 | 2019 | 4883 | 0.300 |
Why?
| Pharmacogenetics | 3 | 2023 | 149 | 0.300 |
Why?
| Professional Competence | 2 | 2018 | 81 | 0.290 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1168 | 0.290 |
Why?
| Etoposide | 4 | 2023 | 149 | 0.290 |
Why?
| CD8-Positive T-Lymphocytes | 4 | 2021 | 686 | 0.280 |
Why?
| Schools, Medical | 2 | 2018 | 121 | 0.280 |
Why?
| Atazanavir Sulfate | 3 | 2016 | 41 | 0.280 |
Why?
| Survival Analysis | 4 | 2015 | 1206 | 0.280 |
Why?
| Cyclopropanes | 6 | 2017 | 81 | 0.280 |
Why?
| Young Adult | 19 | 2023 | 10444 | 0.280 |
Why?
| Alkynes | 6 | 2017 | 53 | 0.280 |
Why?
| Sex Factors | 4 | 2016 | 1706 | 0.270 |
Why?
| Macrophages, Alveolar | 2 | 2020 | 348 | 0.270 |
Why?
| Asia | 5 | 2016 | 53 | 0.270 |
Why?
| Pregnancy Complications, Infectious | 3 | 2018 | 285 | 0.260 |
Why?
| Needs Assessment | 2 | 2018 | 315 | 0.260 |
Why?
| Genotype | 7 | 2023 | 1757 | 0.250 |
Why?
| Treatment Failure | 8 | 2018 | 330 | 0.250 |
Why?
| Case-Control Studies | 8 | 2018 | 3003 | 0.250 |
Why?
| Risk Factors | 16 | 2023 | 8614 | 0.250 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2005 | 11 | 0.250 |
Why?
| Body Composition | 2 | 2020 | 590 | 0.250 |
Why?
| Proportional Hazards Models | 7 | 2018 | 1078 | 0.240 |
Why?
| Disease Progression | 9 | 2021 | 2371 | 0.240 |
Why?
| Curriculum | 4 | 2018 | 813 | 0.240 |
Why?
| Immune System Diseases | 1 | 2004 | 32 | 0.240 |
Why?
| Salvage Therapy | 1 | 2005 | 127 | 0.230 |
Why?
| Lymph Nodes | 3 | 2011 | 415 | 0.230 |
Why?
| Virus Latency | 1 | 2004 | 80 | 0.230 |
Why?
| Dideoxynucleosides | 2 | 2014 | 20 | 0.220 |
Why?
| Feces | 4 | 2021 | 372 | 0.220 |
Why?
| United States | 9 | 2023 | 12137 | 0.220 |
Why?
| Lung | 8 | 2022 | 3521 | 0.210 |
Why?
| Prevalence | 9 | 2019 | 2247 | 0.210 |
Why?
| Insulin-Like Growth Factor I | 2 | 2017 | 286 | 0.210 |
Why?
| Program Evaluation | 2 | 2018 | 820 | 0.210 |
Why?
| Intestinal Mucosa | 2 | 2021 | 532 | 0.210 |
Why?
| Surveys and Questionnaires | 5 | 2022 | 4595 | 0.210 |
Why?
| Adolescent | 16 | 2023 | 17800 | 0.210 |
Why?
| Cardiotoxicity | 1 | 2023 | 27 | 0.210 |
Why?
| Heart Injuries | 1 | 2023 | 37 | 0.210 |
Why?
| Interleukin-10 | 2 | 2023 | 293 | 0.210 |
Why?
| Incidence | 7 | 2023 | 2314 | 0.210 |
Why?
| ADP-ribosyl Cyclase 1 | 2 | 2013 | 36 | 0.200 |
Why?
| Plaque, Atherosclerotic | 1 | 2023 | 46 | 0.200 |
Why?
| Neurocognitive Disorders | 2 | 2019 | 22 | 0.200 |
Why?
| Nevirapine | 2 | 2013 | 16 | 0.200 |
Why?
| Lymphocytes | 2 | 2023 | 327 | 0.200 |
Why?
| Cognition | 4 | 2017 | 990 | 0.200 |
Why?
| Myocarditis | 1 | 2023 | 93 | 0.200 |
Why?
| Emtricitabine | 4 | 2017 | 147 | 0.200 |
Why?
| Personnel Turnover | 1 | 2022 | 27 | 0.190 |
Why?
| Polymerase Chain Reaction | 6 | 2021 | 990 | 0.190 |
Why?
| Gastrointestinal Tract | 2 | 2014 | 169 | 0.190 |
Why?
| Immunogenicity, Vaccine | 1 | 2021 | 25 | 0.190 |
Why?
| Doxorubicin | 1 | 2023 | 286 | 0.190 |
Why?
| Longitudinal Studies | 9 | 2019 | 2384 | 0.190 |
Why?
| Selenium | 3 | 2018 | 31 | 0.190 |
Why?
| B-Cell Maturation Antigen | 1 | 2021 | 4 | 0.190 |
Why?
| Pilot Projects | 5 | 2014 | 1360 | 0.180 |
Why?
| Multivariate Analysis | 4 | 2015 | 1422 | 0.180 |
Why?
| Firmicutes | 1 | 2021 | 17 | 0.180 |
Why?
| Leadership | 3 | 2018 | 291 | 0.180 |
Why?
| Exercise | 2 | 2021 | 1642 | 0.180 |
Why?
| Intention | 1 | 2022 | 142 | 0.180 |
Why?
| Odds Ratio | 2 | 2014 | 951 | 0.180 |
Why?
| Weight Loss | 3 | 2020 | 642 | 0.180 |
Why?
| Filgrastim | 4 | 2004 | 10 | 0.170 |
Why?
| Job Satisfaction | 1 | 2022 | 168 | 0.170 |
Why?
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.170 |
Why?
| Hematopoietic Stem Cells | 2 | 2000 | 338 | 0.170 |
Why?
| Workplace | 1 | 2022 | 221 | 0.170 |
Why?
| Leukapheresis | 1 | 2000 | 21 | 0.170 |
Why?
| Membrane Glycoproteins | 2 | 2013 | 429 | 0.170 |
Why?
| Bacteria | 3 | 2018 | 725 | 0.170 |
Why?
| Suicide | 2 | 2017 | 507 | 0.170 |
Why?
| Vincristine | 1 | 2020 | 98 | 0.170 |
Why?
| B-Lymphocytes | 1 | 2004 | 762 | 0.170 |
Why?
| Pyridazines | 2 | 2012 | 46 | 0.170 |
Why?
| Multiple Myeloma | 1 | 2021 | 98 | 0.170 |
Why?
| Violence | 1 | 2022 | 201 | 0.160 |
Why?
| Brain | 4 | 2019 | 2355 | 0.160 |
Why?
| Clinical Trials as Topic | 2 | 2016 | 926 | 0.160 |
Why?
| Peripheral Nervous System Diseases | 1 | 2020 | 120 | 0.160 |
Why?
| Germ-Free Life | 1 | 2019 | 28 | 0.160 |
Why?
| Atherosclerosis | 1 | 2023 | 342 | 0.160 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2021 | 337 | 0.160 |
Why?
| Hexosaminidases | 1 | 2019 | 17 | 0.160 |
Why?
| Early Detection of Cancer | 1 | 2022 | 305 | 0.160 |
Why?
| Immunotherapy, Adoptive | 1 | 2021 | 184 | 0.160 |
Why?
| Urban Population | 2 | 2013 | 396 | 0.160 |
Why?
| Prevotella | 1 | 2018 | 12 | 0.160 |
Why?
| Cerebral Cortex | 2 | 2013 | 380 | 0.160 |
Why?
| Basal Ganglia | 3 | 2014 | 44 | 0.150 |
Why?
| Bleomycin | 1 | 2020 | 228 | 0.150 |
Why?
| Mouth | 2 | 2015 | 69 | 0.150 |
Why?
| Organophosphonates | 3 | 2013 | 89 | 0.150 |
Why?
| AIDS Vaccines | 1 | 2018 | 41 | 0.150 |
Why?
| Genes, pol | 3 | 2007 | 7 | 0.150 |
Why?
| Follow-Up Studies | 7 | 2021 | 4392 | 0.150 |
Why?
| Drug Combinations | 2 | 2017 | 286 | 0.150 |
Why?
| Capacity Building | 1 | 2018 | 51 | 0.140 |
Why?
| Mutation | 4 | 2015 | 3338 | 0.140 |
Why?
| Cognitive Dysfunction | 2 | 2019 | 282 | 0.140 |
Why?
| Nucleic Acid Conformation | 2 | 1997 | 670 | 0.140 |
Why?
| HIV Protease Inhibitors | 2 | 2016 | 64 | 0.140 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2017 | 76 | 0.140 |
Why?
| Vitamin A Deficiency | 1 | 2017 | 27 | 0.140 |
Why?
| Hospitals | 1 | 2022 | 581 | 0.140 |
Why?
| Didanosine | 2 | 2014 | 13 | 0.140 |
Why?
| Adenine | 3 | 2013 | 218 | 0.140 |
Why?
| Inflammation Mediators | 2 | 2018 | 475 | 0.140 |
Why?
| Herpesvirus 2, Human | 1 | 2017 | 27 | 0.140 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 445 | 0.140 |
Why?
| Dysbiosis | 2 | 2021 | 145 | 0.140 |
Why?
| Coronary Artery Disease | 1 | 2023 | 611 | 0.140 |
Why?
| Financing, Organized | 1 | 2017 | 33 | 0.140 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2014 | 474 | 0.140 |
Why?
| Recombinant Proteins | 4 | 2004 | 1228 | 0.140 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 180 | 0.130 |
Why?
| Immunoglobulin G | 2 | 2023 | 766 | 0.130 |
Why?
| Africa South of the Sahara | 4 | 2020 | 33 | 0.130 |
Why?
| Kaplan-Meier Estimate | 3 | 2013 | 813 | 0.130 |
Why?
| Haiti | 2 | 2016 | 10 | 0.130 |
Why?
| Herpes Simplex | 1 | 2017 | 87 | 0.130 |
Why?
| Lymphocyte Activation | 3 | 2018 | 1036 | 0.130 |
Why?
| Genes, env | 2 | 2007 | 4 | 0.130 |
Why?
| Nervous System Diseases | 1 | 2019 | 254 | 0.130 |
Why?
| Tetrahymena thermophila | 1 | 1996 | 58 | 0.130 |
Why?
| Pregnancy Outcome | 1 | 2018 | 337 | 0.130 |
Why?
| Muscle Strength | 1 | 2018 | 271 | 0.130 |
Why?
| Ghana | 1 | 2015 | 30 | 0.130 |
Why?
| Mental Status and Dementia Tests | 1 | 2016 | 21 | 0.130 |
Why?
| Up-Regulation | 1 | 2019 | 802 | 0.130 |
Why?
| Ambulances | 1 | 2015 | 48 | 0.130 |
Why?
| Molecular Sequence Data | 6 | 2013 | 2783 | 0.130 |
Why?
| DNA, Protozoan | 1 | 2015 | 26 | 0.120 |
Why?
| RNA, Protozoan | 1 | 1995 | 55 | 0.120 |
Why?
| Hepatitis B, Chronic | 1 | 2015 | 18 | 0.120 |
Why?
| Plasmodium falciparum | 1 | 2015 | 27 | 0.120 |
Why?
| Rhodobacter sphaeroides | 3 | 1983 | 7 | 0.120 |
Why?
| Exercise Therapy | 1 | 2018 | 351 | 0.120 |
Why?
| Chemokine CXCL10 | 1 | 2015 | 34 | 0.120 |
Why?
| Time Factors | 3 | 2015 | 6077 | 0.120 |
Why?
| Malaria | 1 | 2015 | 48 | 0.120 |
Why?
| Research | 1 | 2018 | 389 | 0.120 |
Why?
| Cerebrospinal Fluid | 1 | 2015 | 90 | 0.120 |
Why?
| Pre-Exposure Prophylaxis | 1 | 2017 | 179 | 0.120 |
Why?
| Retroviridae Infections | 1 | 1995 | 46 | 0.120 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2015 | 1204 | 0.120 |
Why?
| Bone Morphogenetic Proteins | 1 | 2015 | 132 | 0.120 |
Why?
| Phylogeny | 3 | 2008 | 787 | 0.120 |
Why?
| Cytomegalovirus | 1 | 2015 | 143 | 0.120 |
Why?
| Anthracyclines | 1 | 2014 | 42 | 0.120 |
Why?
| Health Occupations | 1 | 2014 | 28 | 0.110 |
Why?
| Education, Medical, Graduate | 1 | 2018 | 366 | 0.110 |
Why?
| Orchitis | 1 | 2014 | 4 | 0.110 |
Why?
| Penicillin G | 1 | 2014 | 7 | 0.110 |
Why?
| Caribbean Region | 2 | 2011 | 19 | 0.110 |
Why?
| Pregnancy | 5 | 2018 | 5499 | 0.110 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 373 | 0.110 |
Why?
| Health Care Surveys | 1 | 2015 | 541 | 0.110 |
Why?
| Suicidal Ideation | 2 | 2017 | 402 | 0.110 |
Why?
| Syphilis | 1 | 2014 | 26 | 0.110 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2012 | 150 | 0.110 |
Why?
| Stavudine | 1 | 2013 | 8 | 0.110 |
Why?
| Seroepidemiologic Studies | 2 | 2015 | 137 | 0.110 |
Why?
| Metabolic Diseases | 1 | 2014 | 98 | 0.110 |
Why?
| Aging, Premature | 1 | 2013 | 11 | 0.110 |
Why?
| Tropheryma | 1 | 2013 | 5 | 0.110 |
Why?
| Whipple Disease | 1 | 2013 | 6 | 0.110 |
Why?
| HIV Antigens | 3 | 2015 | 17 | 0.110 |
Why?
| Pyrrolidinones | 1 | 2013 | 25 | 0.110 |
Why?
| Biota | 1 | 2013 | 35 | 0.110 |
Why?
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 38 | 0.110 |
Why?
| Problem-Based Learning | 1 | 2014 | 77 | 0.110 |
Why?
| Genitalia, Male | 1 | 2013 | 10 | 0.110 |
Why?
| Body Fat Distribution | 1 | 2013 | 46 | 0.110 |
Why?
| Retinal Detachment | 1 | 2014 | 52 | 0.110 |
Why?
| Genetic Therapy | 1 | 1995 | 256 | 0.110 |
Why?
| Peptide Fragments | 3 | 2007 | 665 | 0.110 |
Why?
| Sequence Analysis, DNA | 3 | 2013 | 722 | 0.110 |
Why?
| Genitalia, Female | 1 | 2013 | 37 | 0.100 |
Why?
| Hospitals, University | 1 | 2013 | 169 | 0.100 |
Why?
| Fever | 2 | 2021 | 280 | 0.100 |
Why?
| Weight Gain | 1 | 2016 | 453 | 0.100 |
Why?
| RNA Stability | 1 | 2013 | 90 | 0.100 |
Why?
| Hepatitis B | 1 | 2013 | 51 | 0.100 |
Why?
| Frail Elderly | 1 | 2013 | 106 | 0.100 |
Why?
| Metagenome | 1 | 2013 | 121 | 0.100 |
Why?
| Urinary Catheterization | 1 | 1992 | 22 | 0.100 |
Why?
| Prostatitis | 1 | 1992 | 18 | 0.100 |
Why?
| Aspergillosis | 1 | 1992 | 23 | 0.100 |
Why?
| Withholding Treatment | 1 | 2012 | 66 | 0.100 |
Why?
| Muscles | 1 | 2013 | 320 | 0.100 |
Why?
| Universities | 1 | 2014 | 338 | 0.100 |
Why?
| Movement | 1 | 2014 | 242 | 0.100 |
Why?
| Respiratory System | 1 | 2013 | 137 | 0.100 |
Why?
| Body Mass Index | 3 | 2014 | 1957 | 0.100 |
Why?
| Neuropsychological Tests | 4 | 2019 | 926 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2015 | 224 | 0.100 |
Why?
| Body Weight | 1 | 2016 | 868 | 0.100 |
Why?
| Education, Medical, Undergraduate | 1 | 2014 | 160 | 0.100 |
Why?
| Catheters, Indwelling | 1 | 1992 | 74 | 0.100 |
Why?
| Lipopolysaccharides | 1 | 2015 | 813 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2023 | 1846 | 0.100 |
Why?
| Unsafe Sex | 1 | 2012 | 57 | 0.100 |
Why?
| Confidence Intervals | 1 | 2012 | 302 | 0.090 |
Why?
| HIV Core Protein p24 | 3 | 2006 | 28 | 0.090 |
Why?
| Paclitaxel | 2 | 2020 | 190 | 0.090 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 907 | 0.090 |
Why?
| Mycobacterium tuberculosis | 2 | 2012 | 269 | 0.090 |
Why?
| Disabled Persons | 1 | 2013 | 130 | 0.090 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2022 | 1128 | 0.090 |
Why?
| Exanthema | 1 | 2012 | 74 | 0.090 |
Why?
| Endothelial Cells | 2 | 2024 | 677 | 0.090 |
Why?
| CD4 Antigens | 1 | 2011 | 123 | 0.090 |
Why?
| Smoking | 2 | 2020 | 1382 | 0.090 |
Why?
| Piperazines | 1 | 1993 | 310 | 0.090 |
Why?
| Kidney Diseases | 1 | 2014 | 349 | 0.090 |
Why?
| Polyneuropathies | 1 | 2011 | 50 | 0.090 |
Why?
| Corpus Callosum | 1 | 2011 | 56 | 0.090 |
Why?
| Americas | 1 | 2010 | 17 | 0.090 |
Why?
| RNA, Ribosomal, 16S | 3 | 2019 | 485 | 0.090 |
Why?
| T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.090 |
Why?
| Patient Compliance | 1 | 2014 | 524 | 0.090 |
Why?
| Specimen Handling | 1 | 2011 | 153 | 0.090 |
Why?
| Bone and Bones | 1 | 2013 | 277 | 0.090 |
Why?
| Interleukin-6 | 3 | 2022 | 673 | 0.090 |
Why?
| HLA-DR Antigens | 1 | 2011 | 219 | 0.090 |
Why?
| Health Personnel | 1 | 2016 | 569 | 0.090 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 396 | 0.090 |
Why?
| Antigens, Viral | 2 | 2021 | 176 | 0.090 |
Why?
| HIV Reverse Transcriptase | 2 | 2004 | 29 | 0.080 |
Why?
| Emigrants and Immigrants | 1 | 2012 | 107 | 0.080 |
Why?
| HIV Fusion Inhibitors | 2 | 2007 | 3 | 0.080 |
Why?
| HIV Envelope Protein gp41 | 2 | 2007 | 6 | 0.080 |
Why?
| Bone Density | 1 | 2013 | 432 | 0.080 |
Why?
| RNA | 1 | 1995 | 806 | 0.080 |
Why?
| Lung Neoplasms | 1 | 2021 | 2159 | 0.080 |
Why?
| Tuberculosis, Pulmonary | 2 | 2013 | 113 | 0.080 |
Why?
| Metabolic Syndrome | 1 | 2012 | 320 | 0.080 |
Why?
| Neuroimaging | 1 | 2011 | 249 | 0.080 |
Why?
| Smokers | 2 | 2020 | 129 | 0.080 |
Why?
| Lung Diseases | 1 | 2015 | 690 | 0.080 |
Why?
| South Africa | 3 | 2016 | 160 | 0.080 |
Why?
| Socioeconomic Factors | 1 | 2012 | 1080 | 0.080 |
Why?
| Epitopes, T-Lymphocyte | 2 | 2006 | 170 | 0.070 |
Why?
| Cytokines | 3 | 2021 | 1824 | 0.070 |
Why?
| Uganda | 1 | 2008 | 69 | 0.070 |
Why?
| Leukocytes, Mononuclear | 2 | 2021 | 489 | 0.070 |
Why?
| Retrospective Studies | 4 | 2023 | 12521 | 0.070 |
Why?
| Base Composition | 2 | 1997 | 75 | 0.070 |
Why?
| Organizational Culture | 2 | 2018 | 119 | 0.070 |
Why?
| Sweating | 1 | 2007 | 23 | 0.070 |
Why?
| Colorado | 3 | 2012 | 4090 | 0.070 |
Why?
| Amino Acid Sequence | 3 | 2006 | 1981 | 0.070 |
Why?
| Blood Vessels | 1 | 2008 | 179 | 0.070 |
Why?
| Vitamin A | 2 | 2018 | 52 | 0.070 |
Why?
| Healthy Volunteers | 2 | 2018 | 191 | 0.070 |
Why?
| Gender Identity | 1 | 2007 | 100 | 0.070 |
Why?
| Purine Nucleosides | 1 | 2006 | 3 | 0.070 |
Why?
| Peru | 2 | 2016 | 54 | 0.060 |
Why?
| Dioxolanes | 1 | 2006 | 6 | 0.060 |
Why?
| Program Development | 2 | 2018 | 339 | 0.060 |
Why?
| Gene Products, gag | 1 | 2006 | 36 | 0.060 |
Why?
| Substrate Specificity | 2 | 1997 | 350 | 0.060 |
Why?
| DNA, Bacterial | 3 | 2019 | 312 | 0.060 |
Why?
| Phospholipids | 3 | 1983 | 194 | 0.060 |
Why?
| Logistic Models | 3 | 2015 | 1829 | 0.060 |
Why?
| Biopsy | 2 | 2020 | 1024 | 0.060 |
Why?
| Selection Bias | 1 | 2005 | 33 | 0.060 |
Why?
| Dizziness | 2 | 2018 | 70 | 0.060 |
Why?
| Disease Reservoirs | 1 | 2004 | 19 | 0.060 |
Why?
| Double-Blind Method | 3 | 2018 | 1656 | 0.060 |
Why?
| Anti-Bacterial Agents | 1 | 2014 | 1471 | 0.060 |
Why?
| HIV Protease | 1 | 2004 | 3 | 0.060 |
Why?
| Comorbidity | 1 | 2009 | 1447 | 0.060 |
Why?
| Linear Models | 3 | 2011 | 768 | 0.060 |
Why?
| HIV Envelope Protein gp120 | 1 | 2004 | 56 | 0.060 |
Why?
| WT1 Proteins | 1 | 2024 | 12 | 0.060 |
Why?
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 20 | 0.060 |
Why?
| Base Sequence | 3 | 1996 | 2114 | 0.060 |
Why?
| Syndrome | 1 | 2004 | 330 | 0.060 |
Why?
| Castleman Disease | 1 | 2003 | 12 | 0.060 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2023 | 56 | 0.050 |
Why?
| Aspartic Acid | 2 | 2014 | 77 | 0.050 |
Why?
| Magnetic Resonance Imaging | 2 | 2011 | 3039 | 0.050 |
Why?
| United Kingdom | 2 | 2014 | 226 | 0.050 |
Why?
| Endemic Diseases | 1 | 2003 | 23 | 0.050 |
Why?
| Glucuronosyltransferase | 1 | 2023 | 9 | 0.050 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2023 | 1880 | 0.050 |
Why?
| Reference Values | 2 | 2016 | 739 | 0.050 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 140 | 0.050 |
Why?
| Choline | 2 | 2014 | 106 | 0.050 |
Why?
| Binding Sites | 2 | 1996 | 1166 | 0.050 |
Why?
| Protein Isoforms | 1 | 2024 | 337 | 0.050 |
Why?
| Interferon-gamma | 1 | 2006 | 719 | 0.050 |
Why?
| Cardiovascular Diseases | 1 | 2013 | 1726 | 0.050 |
Why?
| Chemoradiotherapy | 1 | 2023 | 187 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 924 | 0.050 |
Why?
| Lopinavir | 2 | 2013 | 29 | 0.050 |
Why?
| Deoxycytidine | 2 | 2014 | 138 | 0.050 |
Why?
| Reproducibility of Results | 3 | 2008 | 2764 | 0.050 |
Why?
| Antibodies, Neutralizing | 1 | 2023 | 222 | 0.050 |
Why?
| Ligands | 1 | 2023 | 556 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2021 | 69 | 0.050 |
Why?
| Patient Acuity | 1 | 2021 | 42 | 0.050 |
Why?
| Ritonavir | 2 | 2013 | 71 | 0.050 |
Why?
| Frontal Lobe | 2 | 2014 | 141 | 0.050 |
Why?
| Hemoglobins | 1 | 2023 | 308 | 0.050 |
Why?
| Immunization, Secondary | 1 | 2021 | 82 | 0.050 |
Why?
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 34 | 0.050 |
Why?
| Vidarabine | 1 | 2021 | 26 | 0.050 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 154 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2024 | 428 | 0.050 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 73 | 0.050 |
Why?
| Regression Analysis | 2 | 2014 | 945 | 0.050 |
Why?
| Single-Blind Method | 1 | 2021 | 259 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2023 | 496 | 0.050 |
Why?
| Sensitivity and Specificity | 2 | 2007 | 1690 | 0.040 |
Why?
| Cyclophosphamide | 1 | 2021 | 214 | 0.040 |
Why?
| Cell Line | 3 | 2001 | 2629 | 0.040 |
Why?
| Cells, Cultured | 4 | 2008 | 3861 | 0.040 |
Why?
| Cough | 1 | 2021 | 107 | 0.040 |
Why?
| Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| Genome, Bacterial | 1 | 2021 | 106 | 0.040 |
Why?
| Echocardiography | 1 | 2023 | 569 | 0.040 |
Why?
| Fatty Acids | 1 | 1983 | 380 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 787 | 0.040 |
Why?
| Brazil | 2 | 2016 | 89 | 0.040 |
Why?
| Virion | 1 | 2000 | 73 | 0.040 |
Why?
| Antigens, CD34 | 1 | 2000 | 88 | 0.040 |
Why?
| Immunophenotyping | 1 | 2020 | 274 | 0.040 |
Why?
| Immunologic Memory | 1 | 2001 | 313 | 0.040 |
Why?
| Research Design | 1 | 2005 | 919 | 0.040 |
Why?
| Nitriles | 2 | 2012 | 149 | 0.040 |
Why?
| Animals | 5 | 2019 | 31565 | 0.040 |
Why?
| Diffusion Tensor Imaging | 1 | 2019 | 63 | 0.040 |
Why?
| Atrophy | 1 | 2019 | 152 | 0.040 |
Why?
| Teacher Training | 1 | 2018 | 6 | 0.040 |
Why?
| Motor Skills | 1 | 2019 | 82 | 0.040 |
Why?
| Genes, vpr | 1 | 1997 | 1 | 0.040 |
Why?
| Genes, vif | 1 | 1997 | 3 | 0.040 |
Why?
| Aspartate Aminotransferases | 1 | 2018 | 85 | 0.040 |
Why?
| Trace Elements | 1 | 2018 | 45 | 0.040 |
Why?
| Stillbirth | 1 | 2018 | 57 | 0.040 |
Why?
| Back Pain | 1 | 2018 | 44 | 0.040 |
Why?
| Colon | 1 | 2020 | 232 | 0.040 |
Why?
| Macaca mulatta | 1 | 2018 | 131 | 0.040 |
Why?
| Colony Count, Microbial | 1 | 2018 | 111 | 0.040 |
Why?
| Cytochrome P-450 CYP2B6 | 1 | 2017 | 9 | 0.040 |
Why?
| DNA Primers | 2 | 1996 | 508 | 0.040 |
Why?
| Cytochrome P-450 CYP2A6 | 1 | 2017 | 9 | 0.040 |
Why?
| Adenoviridae | 1 | 2018 | 184 | 0.040 |
Why?
| Principal Component Analysis | 1 | 2018 | 177 | 0.040 |
Why?
| Antigens, CD | 1 | 2020 | 440 | 0.040 |
Why?
| Immunity, Humoral | 1 | 2018 | 112 | 0.040 |
Why?
| Diarrhea | 1 | 2018 | 170 | 0.040 |
Why?
| Abdominal Pain | 1 | 2018 | 134 | 0.040 |
Why?
| In Vitro Techniques | 1 | 2019 | 1003 | 0.040 |
Why?
| Genetic Vectors | 1 | 2018 | 287 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2018 | 167 | 0.030 |
Why?
| Pyrimidines | 2 | 2012 | 374 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 641 | 0.030 |
Why?
| Seroconversion | 1 | 2017 | 45 | 0.030 |
Why?
| Benzoxazoles | 1 | 1996 | 16 | 0.030 |
Why?
| Oligoribonucleotides | 1 | 1996 | 52 | 0.030 |
Why?
| Immunity, Cellular | 1 | 2018 | 247 | 0.030 |
Why?
| Fatigue | 1 | 2018 | 294 | 0.030 |
Why?
| Life Style | 1 | 2018 | 428 | 0.030 |
Why?
| Thailand | 1 | 2016 | 9 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 476 | 0.030 |
Why?
| Patient Selection | 1 | 2000 | 629 | 0.030 |
Why?
| Age Factors | 2 | 2016 | 2885 | 0.030 |
Why?
| Malawi | 1 | 2016 | 45 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 725 | 0.030 |
Why?
| Nutritional Status | 1 | 2018 | 286 | 0.030 |
Why?
| India | 1 | 2016 | 134 | 0.030 |
Why?
| Catalysis | 1 | 1996 | 289 | 0.030 |
Why?
| Verbal Learning | 1 | 2016 | 63 | 0.030 |
Why?
| Parasitemia | 1 | 2015 | 9 | 0.030 |
Why?
| Human Activities | 1 | 2015 | 18 | 0.030 |
Why?
| Hepatitis B virus | 1 | 2015 | 25 | 0.030 |
Why?
| Nuclear Proteins | 1 | 1999 | 591 | 0.030 |
Why?
| Pyridones | 1 | 1996 | 122 | 0.030 |
Why?
| Fellowships and Scholarships | 1 | 2018 | 224 | 0.030 |
Why?
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 1 | 0.030 |
Why?
| Vaccination | 1 | 2023 | 1202 | 0.030 |
Why?
| RNA Splicing | 1 | 1996 | 244 | 0.030 |
Why?
| Carotenoids | 1 | 2015 | 33 | 0.030 |
Why?
| Chronic Disease | 2 | 2014 | 1577 | 0.030 |
Why?
| Tetrahymena | 1 | 1995 | 155 | 0.030 |
Why?
| Premature Birth | 1 | 2018 | 275 | 0.030 |
Why?
| Genotyping Techniques | 1 | 2015 | 69 | 0.030 |
Why?
| Placebos | 1 | 2015 | 197 | 0.030 |
Why?
| Vitamin E | 1 | 2015 | 110 | 0.030 |
Why?
| Schools, Health Occupations | 1 | 2014 | 6 | 0.030 |
Why?
| Retreatment | 1 | 2014 | 67 | 0.030 |
Why?
| Developed Countries | 1 | 2014 | 25 | 0.030 |
Why?
| World Health Organization | 1 | 2014 | 101 | 0.030 |
Why?
| Genetic Markers | 1 | 2015 | 320 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2018 | 1836 | 0.030 |
Why?
| Ophthalmoscopy | 1 | 2014 | 30 | 0.030 |
Why?
| Creatine | 1 | 2014 | 51 | 0.030 |
Why?
| Skin | 1 | 2018 | 653 | 0.030 |
Why?
| Psychology | 1 | 2014 | 82 | 0.030 |
Why?
| Phenotype | 2 | 2014 | 2784 | 0.030 |
Why?
| Protons | 1 | 2014 | 73 | 0.030 |
Why?
| Diffusion of Innovation | 1 | 2014 | 91 | 0.030 |
Why?
| Educational Status | 1 | 2016 | 408 | 0.030 |
Why?
| Group Processes | 1 | 2014 | 53 | 0.030 |
Why?
| Gray Matter | 1 | 2014 | 67 | 0.030 |
Why?
| DNA, Ribosomal | 1 | 2013 | 79 | 0.030 |
Why?
| Raltegravir Potassium | 1 | 2013 | 16 | 0.030 |
Why?
| Global Health | 1 | 2015 | 284 | 0.030 |
Why?
| Inositol | 1 | 2013 | 23 | 0.030 |
Why?
| Bronchoalveolar Lavage | 1 | 2013 | 82 | 0.030 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2015 | 193 | 0.030 |
Why?
| Hepatitis B Surface Antigens | 1 | 2013 | 18 | 0.030 |
Why?
| Kinetics | 1 | 1996 | 1547 | 0.030 |
Why?
| Oligopeptides | 1 | 2014 | 234 | 0.030 |
Why?
| Polymorphism, Genetic | 1 | 2016 | 610 | 0.030 |
Why?
| White Matter | 1 | 2014 | 105 | 0.030 |
Why?
| Hypertension, Pulmonary | 1 | 2003 | 1736 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2014 | 2322 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 367 | 0.030 |
Why?
| Kidney Failure, Chronic | 1 | 2017 | 489 | 0.030 |
Why?
| Cause of Death | 1 | 2014 | 362 | 0.030 |
Why?
| Medication Adherence | 1 | 2017 | 531 | 0.030 |
Why?
| Risk | 1 | 2015 | 810 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 1993 | 300 | 0.020 |
Why?
| Hospitalization | 1 | 2021 | 1762 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1356 | 0.020 |
Why?
| Visual Acuity | 1 | 2014 | 272 | 0.020 |
Why?
| Neurologic Examination | 1 | 2012 | 113 | 0.020 |
Why?
| Blood Coagulation | 1 | 2013 | 200 | 0.020 |
Why?
| Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| Cooperative Behavior | 1 | 2014 | 376 | 0.020 |
Why?
| Psychological Tests | 1 | 2012 | 120 | 0.020 |
Why?
| Glutamic Acid | 1 | 2013 | 210 | 0.020 |
Why?
| Flow Cytometry | 1 | 2015 | 1075 | 0.020 |
Why?
| Suicide, Attempted | 1 | 2014 | 316 | 0.020 |
Why?
| Pyridines | 1 | 2014 | 419 | 0.020 |
Why?
| Data Collection | 1 | 2014 | 618 | 0.020 |
Why?
| Feasibility Studies | 1 | 2014 | 735 | 0.020 |
Why?
| Mood Disorders | 1 | 2012 | 112 | 0.020 |
Why?
| Headache | 1 | 2012 | 132 | 0.020 |
Why?
| Biological Specimen Banks | 1 | 2011 | 94 | 0.020 |
Why?
| Social Support | 1 | 2014 | 528 | 0.020 |
Why?
| Models, Theoretical | 1 | 2014 | 513 | 0.020 |
Why?
| T-Lymphocytes | 1 | 2018 | 1735 | 0.020 |
Why?
| Mozambique | 1 | 2010 | 5 | 0.020 |
Why?
| Students, Medical | 1 | 2014 | 262 | 0.020 |
Why?
| Pyrimidinones | 1 | 2010 | 88 | 0.020 |
Why?
| Antitubercular Agents | 1 | 2011 | 169 | 0.020 |
Why?
| North America | 1 | 2011 | 255 | 0.020 |
Why?
| Thalamus | 1 | 2010 | 74 | 0.020 |
Why?
| Mental Health | 1 | 2015 | 559 | 0.020 |
Why?
| Gene Expression | 1 | 1995 | 1417 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2010 | 249 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2010 | 384 | 0.020 |
Why?
| Neuroglia | 1 | 2010 | 149 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1791 | 0.020 |
Why?
| Organ Size | 1 | 2010 | 434 | 0.020 |
Why?
| Sleep Wake Disorders | 1 | 2012 | 232 | 0.020 |
Why?
| Caspase 7 | 1 | 2008 | 20 | 0.020 |
Why?
| Bone Morphogenetic Protein 4 | 1 | 2008 | 34 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2008 | 119 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2008 | 103 | 0.020 |
Why?
| Clinical Competence | 1 | 2014 | 882 | 0.020 |
Why?
| Caspase 3 | 1 | 2008 | 234 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2013 | 830 | 0.020 |
Why?
| T-Cell Antigen Receptor Specificity | 1 | 2006 | 41 | 0.020 |
Why?
| Fluorides | 1 | 2006 | 43 | 0.020 |
Why?
| Polyurethanes | 1 | 2006 | 34 | 0.020 |
Why?
| Risk Assessment | 1 | 2015 | 2958 | 0.020 |
Why?
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 12 | 0.020 |
Why?
| Methacrylates | 1 | 2006 | 106 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 742 | 0.020 |
Why?
| Computer Simulation | 1 | 2010 | 873 | 0.020 |
Why?
| Sequence Alignment | 1 | 2006 | 323 | 0.020 |
Why?
| Alleles | 1 | 2007 | 789 | 0.010 |
Why?
| Carrier Proteins | 1 | 2008 | 694 | 0.010 |
Why?
| Guanosine Tetraphosphate | 1 | 1983 | 4 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2011 | 2537 | 0.010 |
Why?
| Light | 2 | 1983 | 336 | 0.010 |
Why?
| Cerulenin | 1 | 1983 | 1 | 0.010 |
Why?
| Linolenic Acids | 1 | 1983 | 1 | 0.010 |
Why?
| Linoleic Acids | 1 | 1983 | 4 | 0.010 |
Why?
| Oleic Acids | 1 | 1983 | 10 | 0.010 |
Why?
| Mice | 1 | 2019 | 14843 | 0.010 |
Why?
| Oleic Acid | 1 | 1983 | 30 | 0.010 |
Why?
| Linoleic Acid | 1 | 1983 | 37 | 0.010 |
Why?
| Models, Biological | 1 | 2010 | 1611 | 0.010 |
Why?
| Nucleotides | 1 | 1983 | 112 | 0.010 |
Why?
| Fatty Acids, Unsaturated | 1 | 1983 | 84 | 0.010 |
Why?
| Membrane Lipids | 1 | 1983 | 87 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6306 | 0.010 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 43 | 0.010 |
Why?
| Bacteriological Techniques | 1 | 1981 | 63 | 0.010 |
Why?
| Cardiac Catheterization | 1 | 2003 | 545 | 0.010 |
Why?
| Apoptosis | 1 | 2008 | 2349 | 0.010 |
Why?
| Infant | 1 | 2012 | 7943 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2003 | 1624 | 0.010 |
Why?
| Prognosis | 1 | 2006 | 3315 | 0.010 |
Why?
| HIV Seronegativity | 1 | 1998 | 24 | 0.010 |
Why?
| Substance Abuse, Intravenous | 1 | 1998 | 100 | 0.010 |
Why?
| Antipyrine | 1 | 1996 | 3 | 0.010 |
Why?
| Drug Resistance, Microbial | 1 | 1996 | 66 | 0.010 |
Why?
| Drug Interactions | 1 | 1996 | 337 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1996 | 439 | 0.010 |
Why?
| Intracellular Membranes | 1 | 1981 | 73 | 0.000 |
Why?
| Cell Division | 1 | 1981 | 754 | 0.000 |
Why?
|
|
Campbell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|